Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sevoflurane, quantity: 1 ml/ml - inhalation - excipient ingredients: - sevoflurane sandoz may be used for induction and maintenance of general anaesthesia in adult and paediatric patients undergoing surgery

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - sevoflurane, quantity: 1 ml/ml - inhalation - excipient ingredients: - piramal sevoflurane may be used for induction and maintenance of general anaesthesia in adult and paediatric patients undergoing surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sevoflurane, quantity: 250 ml - inhalation - excipient ingredients: - for induction and maintenance of general anaesthesia in adults and paediatric patients undergoing surgery.

United States - English - NLM (National Library of Medicine)

halocarbon products corp. - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane 1 ml in 1 ml - sevoflurane is indicated for induction and maintenance of general anesthesia in dogs. sevoflurane is contraindicated in dogs with a known sensitivity to sevoflurane or other halogenated agents.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - sevoflurane - liquid for inhalation - sevoflurane 100 %v/v - sevoflurane - sevoflurane is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - sevoflurane - inhalation vapour liquid - 100 per cent - sevoflurane

Israel - English - Ministry of Health

pharma medis - sevoflurane - liquid - sevoflurane 100 %v/v - sevoflurane - sevoflurane - general inhalation anesthetic.

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane 250 ml in 250 ml - sevoflurane, usp is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. sevoflurane, usp should be administered only by persons trained in the administration of general anesthesia. facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, usp should be used.

United States - English - NLM (National Library of Medicine)

halocarbon life sciences, llc - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane 1 ml in 1 ml - sevoflurane is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. sevoflurane should be administered only by persons trained in the administration of general anesthesia. facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used. - known or suspected susceptibility to malignant hyperthermia. - known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.

United States - English - NLM (National Library of Medicine)

piramal critical care inc - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane 1 ml in 1 ml - sevoflurane, usp is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. sevoflurane, usp should be administered only by persons trained in the administration of general anesthesia. facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, usp should be used. • known or suspected genetic susceptibility to malignant hyperthermia. (see warnings - malignant hyperthermia, clinical pharmacology - pharmacogenomics ). • known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.